Vivus ($VVUS) signed a partnership deal in June with Italy's Menarini to help it roll out its erectile dysfunction drug Stendra (Spedra in the EU). Now the company has picked Sanofi's ($SNY) contract manufacturing arm, Chimie, to manufacture the active pharmaceutical ingredient (API) for Stendra (avanafil). Chimie will produce the API exclusively in the U.S. and on a semiexclusive basis in the EU and Latin America. Mountain View, CA-based Vivus says it expects to get the Sanofi facilities approved for production by regulators by June 30, 2015. Until then, it will continue to get the API from Mitsubishi Tanabe Pharma. The FDA approved the drug last year, but Vivus was waiting to find a partner before taking it to market. Release | More